FindTrial
Sign In

Using large models and artificial intelligence methods to study the prognosis and treatment response of multiple myeloma

Using large models and artificial intelligence methods to study the prognosis and treatment response of multiple myeloma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110144
Enrollment
Unknown
Registered
2025-10-09
Start date
2025-10-10
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Large language model group:None

Sponsors

The First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with symptomatic multiple myeloma according to the IMWG 2016 criteria; 2. aged >=18 years; 3. with complete baseline information, treatment regimen, and follow-up data available.

Exclusion criteria

Exclusion criteria: 1. Patients with concurrent other primary malignancies who still require treatment; 2. Patients diagnosed with smoldering myeloma or monoclonal gammopathy of undetermined significance; 3. Pregnant or lactating women; 4. Patients with severely incomplete clinical data that preclude reliable assessment; 5. Patients deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
accuracy;Area under the ROC curve;—

Countries

China

Contacts

Public ContactChen Bin

The First Affiliated Hospital of Zhejiang University School of Medicine

ttbin@zju.edu.cn+86 137 3800 6070

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026